Mexican Health Authority Green Lights TearLab’s (TEAR) Osmolarity System
Shares of TearLab Corporation (Nasdaq:TEAR) climbed more than 10% in pre-market trade Wednesday after the company said that the Mexican health authority (COFEPRIS) gave green light to its TearLab Osmolarity System – an in vitro diagnostic tear testing platform for dry eye disease -.
The in-vitro diagnostic company plans to launch the TearLab Osmolarity System in Mexico during the first half of this year.
TEAR stock closed at $0.65, up $0.01 (or +1.56%) on Tuesday’s trading session.
TearLab, which develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care, has 53.60M shares outstanding and TEAR stock 52-week range is from $0.39 to $1.46 per share. At close on Tuesday, the company had a market capitalization of $34.84M.
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/